APO Research
Talk to an analyst

APO RESEARCH · REPORT

Sterile Injectable CDMO

Compare research editions
View pricing & licenses

Selected research

Industry Research

Sterile Injectable CDMO Industry Research Report 2026

30 January 2026137 pages

Choose your research edition.

Industry ResearchSterile Injectable CDMO Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Sterile Injectable CDMO Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Sterile Injectable CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Sterile Injectable CDMO Market Outlook and Growth Opportunities 2026214 pages · $4,250 USDMarket Analysis & ForecastGlobal Sterile Injectable CDMO Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

The global Sterile Injectable CDMO market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Sterile Injectable CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Sterile Injectable CDMO market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Sterile Injectable CDMO market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Sterile Injectable CDMO include Abbvie, Famar, Polfa Tarchomin, Pfizer, Quotient Sciences, Temad Co., Tianjin Hankang Pharmaceutical Biotechnology, Fareva and Sharp, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

Read the full market overview

This report quantifies the global Sterile Injectable CDMO market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Sterile Injectable CDMO.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Sterile Injectable CDMO Market by Company

Abbvie

Famar

Polfa Tarchomin

Pfizer

Quotient Sciences

Temad Co.

Tianjin Hankang Pharmaceutical Biotechnology

Fareva

Sharp

Astral SteriTech

Evonik

Aurigene Pharmaceutical Services

Prague Scientific

Ethypharm

TriRx Pharmaceutical Services

Biophrama Group

Gensenta Pharmaceuticals

BioTechnique

Mithra CDMo

S.C. Rompharm Company SRL

Flagship Biotech International Pvt. Ltd

Curida AS

BirgiMefar Group

Brooks Laboratories Limited

Sterile Injectable CDMO Segment by Type

Preclinical Manufacturing

Clinical Manufacturing

Commercial Manufacturing

Sterile Injectable CDMO Segment by Application

Pharmaceutical Company

Research Institute

Other

Sterile Injectable CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sterile Injectable CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Sterile Injectable CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sterile Injectable CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Sterile Injectable CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Sterile Injectable CDMO Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Sterile Injectable CDMO Revenue Market Share by Type (2021-2026) Table 7. Global Sterile Injectable CDMO Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Sterile Injectable CDMO Revenue Market Share by Type (2027-2032) Table 9. Global Sterile Injectable CDMO Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Sterile Injectable CDMO Revenue Market Share by Application (2021-2026) Table 11. Global Sterile Injectable CDMO Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Sterile Injectable CDMO Revenue Market Share by Application (2027-2032) Table 13. Global Sterile Injectable CDMO Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Sterile Injectable CDMO Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Sterile Injectable CDMO Market Share by Region (2021-2026) Table 16. Global Sterile Injectable CDMO Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Sterile Injectable CDMO Market Share by Region (2027-2032) Table 18. Sterile Injectable CDMO Industry Trends Table 19. Sterile Injectable CDMO Industry Drivers Table 20. Sterile Injectable CDMO Industry Opportunities and Challenges Table 21. Sterile Injectable CDMO Market Restraints Table 22. Global Top Sterile Injectable CDMO Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Sterile Injectable CDMO Revenue Market Share by Players (2021-2026) Table 24. Global Sterile Injectable CDMO Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Sterile Injectable CDMO, Headquarters and Area Served Table 26. Global Sterile Injectable CDMO Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Sterile Injectable CDMO by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Sterile Injectable CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Sterile Injectable CDMO Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Sterile Injectable CDMO Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Sterile Injectable CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Sterile Injectable CDMO Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Sterile Injectable CDMO Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Sterile Injectable CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Sterile Injectable CDMO Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Sterile Injectable CDMO Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Sterile Injectable CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Sterile Injectable CDMO Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Sterile Injectable CDMO Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Sterile Injectable CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Sterile Injectable CDMO Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Sterile Injectable CDMO Market Size by Country (2027-2032) & (US$ Million) Table 45. Abbvie Company Information Table 46. Abbvie Business Overview Table 47. Abbvie Revenue in Sterile Injectable CDMO Business (2021-2026) & (US$ Million) Table 48. Abbvie Sterile Injectable CDMO Product Portfolio Table 49. Abbvie Recent Developments Table 50. Famar Company Information Table 51. Famar Business Overview Table 52. Famar Revenue in Sterile Injectable CDMO Business (2021-2026) & (US$ Million) Table 53. Famar Sterile Injectable CDMO Product Portfolio Table 54. Famar Recent Developments Table 55. Polfa Tarchomin Company Information Table 56. Polfa Tarchomin Business Overview Table 57. Polfa Tarchomin Revenue in Sterile Injectable CDMO Business (2021-2026) & (US$ Million) Table 58. Polfa Tarchomin Sterile Injectable CDMO Product Portfolio Table 59. Polfa Tarchomin Recent Developments Table 60. Pfizer Company Information Table 61. Pfizer Business Overview Table 62. Pfizer Revenue in Sterile Injectable CDMO Business (2021-2026) & (US$ Million) Table 63. Pfizer Sterile Injectable CDMO Product Portfolio Table 64. Pfizer Recent Developments Table 65. Quotient Sciences Company Information Table 66. Quotient Sciences Business Overview Table 67. Quotient Sciences Revenue in Sterile Injectable CDMO Business (2021-2026) & (US$ Million) Table 68. Quotient Sciences Sterile Injectable CDMO Product Portfolio Table 69. Quotient Sciences Recent Developments Table 70. Temad Co. Company Information Table 71. Temad Co. Business Overview Table 72. Temad Co. Revenue in Sterile Injectable CDMO Business (2021-2026) & (US$ Million) Table 73. Temad Co. Sterile Injectable CDMO Product Portfolio Table 74. Temad Co. Recent Developments Table 75. Tianjin Hankang Pharmaceutical Biotechnology Company Information Table 76. Tianjin Hankang Pharmaceutical Biotechnology Business Overview Table 77. Tianjin Hankang Pharmaceutical Biotechnology Revenue in Sterile Injectable CDMO Business (2021-2026) & (US$ Million) Table 78. Tianjin Hankang Pharmaceutical Biotechnology Sterile Injectable CDMO Product Portfolio Table 79. Tianjin Hankang Pharmaceutical Biotechnology Recent Developments Table 80. Fareva Company Information Table 81. Fareva Business Overview Table 82. Fareva Revenue in Sterile Injectable CDMO Business (2021-2026) & (US$ Million) Table 83. Fareva Sterile Injectable CDMO Product Portfolio Table 84. Fareva Recent Developments Table 85. Sharp Company Information Table 86. Sharp Business Overview Table 87. Sharp Revenue in Sterile Injectable CDMO Business (2021-2026) & (US$ Million) Table 88. Sharp Sterile Injectable CDMO Product Portfolio Table 89. Sharp Recent Developments Table 90. Astral SteriTech Company Information Table 91. Astral SteriTech Business Overview Table 92. Astral SteriTech Revenue in Sterile Injectable CDMO Business (2021-2026) & (US$ Million) Table 93. Astral SteriTech Sterile Injectable CDMO Product Portfolio Table 94. Astral SteriTech Recent Developments Table 95. Evonik Company Information Table 96. Evonik Business Overview Table 97. Evonik Revenue in Sterile Injectable CDMO Business (2021-2026) & (US$ Million) Table 98. Evonik Sterile Injectable CDMO Product Portfolio Table 99. Evonik Recent Developments Table 100. Aurigene Pharmaceutical Services Company Information Table 101. Aurigene Pharmaceutical Services Business Overview Table 102. Aurigene Pharmaceutical Services Revenue in Sterile Injectable CDMO Business (2021-2026) & (US$ Million) Table 103. Aurigene Pharmaceutical Services Sterile Injectable CDMO Product Portfolio Table 104. Aurigene Pharmaceutical Services Recent Developments Table 105. Prague Scientific Company Information Table 106. Prague Scientific Business Overview Table 107. Prague Scientific Revenue in Sterile Injectable CDMO Business (2021-2026) & (US$ Million) Table 108. Prague Scientific Sterile Injectable CDMO Product Portfolio Table 109. Prague Scientific Recent Developments Table 110. Ethypharm Company Information Table 111. Ethypharm Business Overview Table 112. Ethypharm Revenue in Sterile Injectable CDMO Business (2021-2026) & (US$ Million) Table 113. Ethypharm Sterile Injectable CDMO Product Portfolio Table 114. Ethypharm Recent Developments Table 115. TriRx Pharmaceutical Services Company Information Table 116. TriRx Pharmaceutical Services Business Overview Table 117. TriRx Pharmaceutical Services Revenue in Sterile Injectable CDMO Business (2021-2026) & (US$ Million) Table 118. TriRx Pharmaceutical Services Sterile Injectable CDMO Product Portfolio Table 119. TriRx Pharmaceutical Services Recent Developments Table 120. Biophrama Group Company Information Table 121. Biophrama Group Business Overview Table 122. Biophrama Group Revenue in Sterile Injectable CDMO Business (2021-2026) & (US$ Million) Table 123. Biophrama Group Sterile Injectable CDMO Product Portfolio Table 124. Biophrama Group Recent Developments Table 125. Gensenta Pharmaceuticals Company Information Table 126. Gensenta Pharmaceuticals Business Overview Table 127. Gensenta Pharmaceuticals Revenue in Sterile Injectable CDMO Business (2021-2026) & (US$ Million) Table 128. Gensenta Pharmaceuticals Sterile Injectable CDMO Product Portfolio Table 129. Gensenta Pharmaceuticals Recent Developments Table 130. BioTechnique Company Information Table 131. BioTechnique Business Overview Table 132. BioTechnique Revenue in Sterile Injectable CDMO Business (2021-2026) & (US$ Million) Table 133. BioTechnique Sterile Injectable CDMO Product Portfolio Table 134. BioTechnique Recent Developments Table 135. Mithra CDMo Company Information Table 136. Mithra CDMo Business Overview Table 137. Mithra CDMo Revenue in Sterile Injectable CDMO Business (2021-2026) & (US$ Million) Table 138. Mithra CDMo Sterile Injectable CDMO Product Portfolio Table 139. Mithra CDMo Recent Developments Table 140. S.C. Rompharm Company SRL Company Information Table 141. S.C. Rompharm Company SRL Business Overview Table 142. S.C. Rompharm Company SRL Revenue in Sterile Injectable CDMO Business (2021-2026) & (US$ Million) Table 143. S.C. Rompharm Company SRL Sterile Injectable CDMO Product Portfolio Table 144. S.C. Rompharm Company SRL Recent Developments Table 145. Flagship Biotech International Pvt. Ltd Company Information Table 146. Flagship Biotech International Pvt. Ltd Business Overview Table 147. Flagship Biotech International Pvt. Ltd Revenue in Sterile Injectable CDMO Business (2021-2026) & (US$ Million) Table 148. Flagship Biotech International Pvt. Ltd Sterile Injectable CDMO Product Portfolio Table 149. Flagship Biotech International Pvt. Ltd Recent Developments Table 150. Curida AS Company Information Table 151. Curida AS Business Overview Table 152. Curida AS Revenue in Sterile Injectable CDMO Business (2021-2026) & (US$ Million) Table 153. Curida AS Sterile Injectable CDMO Product Portfolio Table 154. Curida AS Recent Developments Table 155. BirgiMefar Group Company Information Table 156. BirgiMefar Group Business Overview Table 157. BirgiMefar Group Revenue in Sterile Injectable CDMO Business (2021-2026) & (US$ Million) Table 158. BirgiMefar Group Sterile Injectable CDMO Product Portfolio Table 159. BirgiMefar Group Recent Developments Table 160. Brooks Laboratories Limited Company Information Table 161. Brooks Laboratories Limited Business Overview Table 162. Brooks Laboratories Limited Revenue in Sterile Injectable CDMO Business (2021-2026) & (US$ Million) Table 163. Brooks Laboratories Limited Sterile Injectable CDMO Product Portfolio Table 164. Brooks Laboratories Limited Recent Developments Table 165. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Sterile Injectable CDMO Product Image Figure 5. Global Sterile Injectable CDMO Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Sterile Injectable CDMO Market Share by Type: 2025 VS 2032 Figure 7. Preclinical Manufacturing Product Figure 8. Clinical Manufacturing Product Figure 9. Commercial Manufacturing Product Figure 10. Global Sterile Injectable CDMO Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Sterile Injectable CDMO Market Share by Application: 2025 VS 2032 Figure 12. Pharmaceutical Company Product Figure 13. Research Institute Product Figure 14. Other Product Figure 15. Global Sterile Injectable CDMO Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 16. Global Sterile Injectable CDMO Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Sterile Injectable CDMO Market Share by Region: 2025 VS 2032 Figure 18. Global Sterile Injectable CDMO Market Share by Players in 2025 Figure 19. Global Sterile Injectable CDMO Manufacturers Established Date Figure 20. Global Top 5 and 10 Sterile Injectable CDMO Players Market Share by Revenue in 2025 Figure 21. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. North America Sterile Injectable CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Sterile Injectable CDMO Market Share by Country (2021-2032) Figure 24. United States Sterile Injectable CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Canada Sterile Injectable CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 26. Mexico Sterile Injectable CDMO Market Share by Country (2021-2032) Figure 27. Europe Sterile Injectable CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 28. Europe Sterile Injectable CDMO Market Share by Country (2021-2032) Figure 29. Germany Sterile Injectable CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 30. France Sterile Injectable CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. U.K. Sterile Injectable CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. Italy Sterile Injectable CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Spain Sterile Injectable CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. Russia Sterile Injectable CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Netherlands Sterile Injectable CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Nordic Countries Sterile Injectable CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Sterile Injectable CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Sterile Injectable CDMO Market Share by Country (2021-2032) Figure 39. China Sterile Injectable CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 40. Japan Sterile Injectable CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. South Korea Sterile Injectable CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 42. India Sterile Injectable CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 43. India Sterile Injectable CDMO Market Share by Country (2021-2032) Figure 44. Australia Sterile Injectable CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 45. China Taiwan Sterile Injectable CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 46. Southeast Asia Sterile Injectable CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. South America Sterile Injectable CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 48. South America Sterile Injectable CDMO Market Share by Country (2021-2032) Figure 49. Brazil Sterile Injectable CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 50. Argentina Sterile Injectable CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 51. Chile Sterile Injectable CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. Colombia Sterile Injectable CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 53. Peru Sterile Injectable CDMO Market Size YoY Growth (2021-2032) & (US$ Million) Figure 54. Abbvie Revenue Growth Rate in Sterile Injectable CDMO Business (2021-2026) Figure 55. Famar Revenue Growth Rate in Sterile Injectable CDMO Business (2021-2026) Figure 56. Polfa Tarchomin Revenue Growth Rate in Sterile Injectable CDMO Business (2021-2026) Figure 57. Pfizer Revenue Growth Rate in Sterile Injectable CDMO Business (2021-2026) Figure 58. Quotient Sciences Revenue Growth Rate in Sterile Injectable CDMO Business (2021-2026) Figure 59. Temad Co. Revenue Growth Rate in Sterile Injectable CDMO Business (2021-2026) Figure 60. Tianjin Hankang Pharmaceutical Biotechnology Revenue Growth Rate in Sterile Injectable CDMO Business (2021-2026) Figure 61. Fareva Revenue Growth Rate in Sterile Injectable CDMO Business (2021-2026) Figure 62. Sharp Revenue Growth Rate in Sterile Injectable CDMO Business (2021-2026) Figure 63. Astral SteriTech Revenue Growth Rate in Sterile Injectable CDMO Business (2021-2026) Figure 64. Evonik Revenue Growth Rate in Sterile Injectable CDMO Business (2021-2026) Figure 65. Aurigene Pharmaceutical Services Revenue Growth Rate in Sterile Injectable CDMO Business (2021-2026) Figure 66. Prague Scientific Revenue Growth Rate in Sterile Injectable CDMO Business (2021-2026) Figure 67. Ethypharm Revenue Growth Rate in Sterile Injectable CDMO Business (2021-2026) Figure 68. TriRx Pharmaceutical Services Revenue Growth Rate in Sterile Injectable CDMO Business (2021-2026) Figure 69. Biophrama Group Revenue Growth Rate in Sterile Injectable CDMO Business (2021-2026) Figure 70. Gensenta Pharmaceuticals Revenue Growth Rate in Sterile Injectable CDMO Business (2021-2026) Figure 71. BioTechnique Revenue Growth Rate in Sterile Injectable CDMO Business (2021-2026) Figure 72. Mithra CDMo Revenue Growth Rate in Sterile Injectable CDMO Business (2021-2026) Figure 73. S.C. Rompharm Company SRL Revenue Growth Rate in Sterile Injectable CDMO Business (2021-2026) Figure 74. Flagship Biotech International Pvt. Ltd Revenue Growth Rate in Sterile Injectable CDMO Business (2021-2026) Figure 75. Curida AS Revenue Growth Rate in Sterile Injectable CDMO Business (2021-2026) Figure 76. BirgiMefar Group Revenue Growth Rate in Sterile Injectable CDMO Business (2021-2026) Figure 77. Brooks Laboratories Limited Revenue Growth Rate in Sterile Injectable CDMO Business (2021-2026)

Scope & coverage.

Types
  • Preclinical Manufacturing
  • Clinical Manufacturing
  • Commercial Manufacturing
Applications
  • Pharmaceutical Company
  • Research Institute
  • Other
Companies covered
  • Abbvie
  • Famar
  • Polfa Tarchomin
  • Pfizer
  • Quotient Sciences
  • Temad Co.
  • Tianjin Hankang Pharmaceutical Biotechnology
  • Fareva
  • Sharp
  • Astral SteriTech
  • Evonik
  • Aurigene Pharmaceutical Services
  • Prague Scientific
  • Ethypharm
  • TriRx Pharmaceutical Services
  • Biophrama Group
  • Gensenta Pharmaceuticals
  • BioTechnique
  • Mithra CDMo
  • S.C. Rompharm Company SRL
  • Flagship Biotech International Pvt. Ltd
  • Curida AS
  • BirgiMefar Group
  • Brooks Laboratories Limited

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Sterile Injectable CDMO by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  4. 2.2.2 Preclinical Manufacturing
  5. 2.2.3 Clinical Manufacturing
  6. 2.2.4 Commercial Manufacturing
  7. 2.3 Sterile Injectable CDMO by Application
  8. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  9. 2.3.2 Pharmaceutical Company
  10. 2.3.3 Research Institute
  11. 2.3.4 Other
  12. 2.4 Assumptions and Limitations
3 Sterile Injectable CDMO Breakdown Data by Type
  1. 3.1 Global Sterile Injectable CDMO Historic Market Size by Type (2021-2026)
  2. 3.2 Global Sterile Injectable CDMO Forecasted Market Size by Type (2027-2032)
4 Sterile Injectable CDMO Breakdown Data by Application
  1. 4.1 Global Sterile Injectable CDMO Historic Market Size by Application (2021-2026)
  2. 4.2 Global Sterile Injectable CDMO Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
  1. 5.1 Global Sterile Injectable CDMO Market Perspective (2021-2032)
  2. 5.2 Global Sterile Injectable CDMO Growth Trends by Region
  3. 5.2.1 Global Sterile Injectable CDMO Market Size by Region: 2021 VS 2025 VS 2032
  4. 5.2.2 Sterile Injectable CDMO Historic Market Size by Region (2021-2026)
  5. 5.2.3 Sterile Injectable CDMO Forecasted Market Size by Region (2027-2032)
  6. 5.3 Sterile Injectable CDMO Market Dynamics
  7. 5.3.1 Sterile Injectable CDMO Industry Trends
  8. 5.3.2 Sterile Injectable CDMO Market Drivers
  9. 5.3.3 Sterile Injectable CDMO Market Challenges
  10. 5.3.4 Sterile Injectable CDMO Market Restraints
6 Market Competitive Landscape by Players
  1. 6.1 Global Top Sterile Injectable CDMO Players by Revenue
  2. 6.1.1 Global Top Sterile Injectable CDMO Players by Revenue (2021-2026)
  3. 6.1.2 Global Sterile Injectable CDMO Revenue Market Share by Players (2021-2026)
  4. 6.2 Global Sterile Injectable CDMO Industry Players Ranking, 2023 VS 2024 VS 2025
  5. 6.3 Global Key Players of Sterile Injectable CDMO Head Office and Area Served
  6. 6.4 Global Sterile Injectable CDMO Players, Product Type & Application
  7. 6.5 Global Sterile Injectable CDMO Manufacturers Established Date
  8. 6.6 Global Sterile Injectable CDMO Market CR5 and HHI
  9. 6.7 Global Players Mergers & Acquisition
7 North America
  1. 7.1 North America Sterile Injectable CDMO Market Size (2021-2032)
  2. 7.2 North America Sterile Injectable CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 7.3 North America Sterile Injectable CDMO Market Size by Country (2021-2026)
  4. 7.4 North America Sterile Injectable CDMO Market Size by Country (2027-2032)
  5. 7.5 United States
  6. 7.5 United States
  7. 7.6 Canada
  8. 7.7 Mexico
8 Europe
  1. 8.1 Europe Sterile Injectable CDMO Market Size (2021-2032)
  2. 8.2 Europe Sterile Injectable CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 8.3 Europe Sterile Injectable CDMO Market Size by Country (2021-2026)
  4. 8.4 Europe Sterile Injectable CDMO Market Size by Country (2027-2032)
  5. 8.5 Germany
  6. 8.6 France
  7. 8.7 U.K.
  8. 8.8 Italy
  9. 8.9 Spain
  10. 8.10 Russia
  11. 8.11 Netherlands
  12. 8.12 Nordic Countries
9 Asia-Pacific
  1. 9.1 Asia-Pacific Sterile Injectable CDMO Market Size (2021-2032)
  2. 9.2 Asia-Pacific Sterile Injectable CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 9.3 Asia-Pacific Sterile Injectable CDMO Market Size by Country (2021-2026)
  4. 9.4 Asia-Pacific Sterile Injectable CDMO Market Size by Country (2027-2032)
  5. 9.5 China
  6. 9.6 Japan
  7. 9.7 South Korea
  8. 9.8 India
  9. 9.9 Australia
  10. 9.10 China Taiwan
  11. 9.11 Southeast Asia
10 South America
  1. 10.1 South America Sterile Injectable CDMO Market Size (2021-2032)
  2. 10.2 South America Sterile Injectable CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 10.3 South America Sterile Injectable CDMO Market Size by Country (2021-2026)
  4. 10.4 South America Sterile Injectable CDMO Market Size by Country (2027-2032)
  5. 10.5 Brazil
  6. 10.6 Argentina
  7. 10.7 Chile
  8. 10.8 Colombia
  9. 10.9 Peru
11 Middle East & Africa
  1. 11.1 Middle East & Africa Sterile Injectable CDMO Market Size (2021-2032)
  2. 11.2 Middle East & Africa Sterile Injectable CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 11.3 Middle East & Africa Sterile Injectable CDMO Market Size by Country (2021-2026)
  4. 11.4 Middle East & Africa Sterile Injectable CDMO Market Size by Country (2027-2032)
  5. 11.5 Saudi Arabia
  6. 11.6 Israel
  7. 11.7 United Arab Emirates
  8. 11.8 Turkey
  9. 11.9 Iran
  10. 11.10 Egypt
12 Players Profiled
  1. 12.1 Abbvie
  2. 12.1.1 Abbvie Company Information
  3. 12.1.2 Abbvie Business Overview
  4. 12.1.3 Abbvie Revenue in Sterile Injectable CDMO Business (2021-2026)
  5. 12.1.4 Abbvie Sterile Injectable CDMO Product Portfolio
  6. 12.1.5 Abbvie Recent Developments
  7. 12.2 Famar
  8. 12.2.1 Famar Company Information
  9. 12.2.2 Famar Business Overview
  10. 12.2.3 Famar Revenue in Sterile Injectable CDMO Business (2021-2026)
  11. 12.2.4 Famar Sterile Injectable CDMO Product Portfolio
  12. 12.2.5 Famar Recent Developments
  13. 12.3 Polfa Tarchomin
  14. 12.3.1 Polfa Tarchomin Company Information
  15. 12.3.2 Polfa Tarchomin Business Overview
  16. 12.3.3 Polfa Tarchomin Revenue in Sterile Injectable CDMO Business (2021-2026)
  17. 12.3.4 Polfa Tarchomin Sterile Injectable CDMO Product Portfolio
  18. 12.3.5 Polfa Tarchomin Recent Developments
  19. 12.4 Pfizer
  20. 12.4.1 Pfizer Company Information
  21. 12.4.2 Pfizer Business Overview
  22. 12.4.3 Pfizer Revenue in Sterile Injectable CDMO Business (2021-2026)
  23. 12.4.4 Pfizer Sterile Injectable CDMO Product Portfolio
  24. 12.4.5 Pfizer Recent Developments
  25. 12.5 Quotient Sciences
  26. 12.5.1 Quotient Sciences Company Information
  27. 12.5.2 Quotient Sciences Business Overview
  28. 12.5.3 Quotient Sciences Revenue in Sterile Injectable CDMO Business (2021-2026)
  29. 12.5.4 Quotient Sciences Sterile Injectable CDMO Product Portfolio
  30. 12.5.5 Quotient Sciences Recent Developments
  31. 12.6 Temad Co.
  32. 12.6.1 Temad Co. Company Information
  33. 12.6.2 Temad Co. Business Overview
  34. 12.6.3 Temad Co. Revenue in Sterile Injectable CDMO Business (2021-2026)
  35. 12.6.4 Temad Co. Sterile Injectable CDMO Product Portfolio
  36. 12.6.5 Temad Co. Recent Developments
  37. 12.7 Tianjin Hankang Pharmaceutical Biotechnology
  38. 12.7.1 Tianjin Hankang Pharmaceutical Biotechnology Company Information
  39. 12.7.2 Tianjin Hankang Pharmaceutical Biotechnology Business Overview
  40. 12.7.3 Tianjin Hankang Pharmaceutical Biotechnology Revenue in Sterile Injectable CDMO Business (2021-2026)
  41. 12.7.4 Tianjin Hankang Pharmaceutical Biotechnology Sterile Injectable CDMO Product Portfolio
  42. 12.7.5 Tianjin Hankang Pharmaceutical Biotechnology Recent Developments
  43. 12.8 Fareva
  44. 12.8.1 Fareva Company Information
  45. 12.8.2 Fareva Business Overview
  46. 12.8.3 Fareva Revenue in Sterile Injectable CDMO Business (2021-2026)
  47. 12.8.4 Fareva Sterile Injectable CDMO Product Portfolio
  48. 12.8.5 Fareva Recent Developments
  49. 12.9 Sharp
  50. 12.9.1 Sharp Company Information
  51. 12.9.2 Sharp Business Overview
  52. 12.9.3 Sharp Revenue in Sterile Injectable CDMO Business (2021-2026)
  53. 12.9.4 Sharp Sterile Injectable CDMO Product Portfolio
  54. 12.9.5 Sharp Recent Developments
  55. 12.10 Astral SteriTech
  56. 12.10.1 Astral SteriTech Company Information
  57. 12.10.2 Astral SteriTech Business Overview
  58. 12.10.3 Astral SteriTech Revenue in Sterile Injectable CDMO Business (2021-2026)
  59. 12.10.4 Astral SteriTech Sterile Injectable CDMO Product Portfolio
  60. 12.10.5 Astral SteriTech Recent Developments
  61. 12.11 Evonik
  62. 12.11.1 Evonik Company Information
  63. 12.11.2 Evonik Business Overview
  64. 12.11.3 Evonik Revenue in Sterile Injectable CDMO Business (2021-2026)
  65. 12.11.4 Evonik Sterile Injectable CDMO Product Portfolio
  66. 12.11.5 Evonik Recent Developments
  67. 12.12 Aurigene Pharmaceutical Services
  68. 12.12.1 Aurigene Pharmaceutical Services Company Information
  69. 12.12.2 Aurigene Pharmaceutical Services Business Overview
  70. 12.12.3 Aurigene Pharmaceutical Services Revenue in Sterile Injectable CDMO Business (2021-2026)
  71. 12.12.4 Aurigene Pharmaceutical Services Sterile Injectable CDMO Product Portfolio
  72. 12.12.5 Aurigene Pharmaceutical Services Recent Developments
  73. 12.13 Prague Scientific
  74. 12.13.1 Prague Scientific Company Information
  75. 12.13.2 Prague Scientific Business Overview
  76. 12.13.3 Prague Scientific Revenue in Sterile Injectable CDMO Business (2021-2026)
  77. 12.13.4 Prague Scientific Sterile Injectable CDMO Product Portfolio
  78. 12.13.5 Prague Scientific Recent Developments
  79. 12.14 Ethypharm
  80. 12.14.1 Ethypharm Company Information
  81. 12.14.2 Ethypharm Business Overview
  82. 12.14.3 Ethypharm Revenue in Sterile Injectable CDMO Business (2021-2026)
  83. 12.14.4 Ethypharm Sterile Injectable CDMO Product Portfolio
  84. 12.14.5 Ethypharm Recent Developments
  85. 12.15 TriRx Pharmaceutical Services
  86. 12.15.1 TriRx Pharmaceutical Services Company Information
  87. 12.15.2 TriRx Pharmaceutical Services Business Overview
  88. 12.15.3 TriRx Pharmaceutical Services Revenue in Sterile Injectable CDMO Business (2021-2026)
  89. 12.15.4 TriRx Pharmaceutical Services Sterile Injectable CDMO Product Portfolio
  90. 12.15.5 TriRx Pharmaceutical Services Recent Developments
  91. 12.16 Biophrama Group
  92. 12.16.1 Biophrama Group Company Information
  93. 12.16.2 Biophrama Group Business Overview
  94. 12.16.3 Biophrama Group Revenue in Sterile Injectable CDMO Business (2021-2026)
  95. 12.16.4 Biophrama Group Sterile Injectable CDMO Product Portfolio
  96. 12.16.5 Biophrama Group Recent Developments
  97. 12.17 Gensenta Pharmaceuticals
  98. 12.17.1 Gensenta Pharmaceuticals Company Information
  99. 12.17.2 Gensenta Pharmaceuticals Business Overview
  100. 12.17.3 Gensenta Pharmaceuticals Revenue in Sterile Injectable CDMO Business (2021-2026)
  101. 12.17.4 Gensenta Pharmaceuticals Sterile Injectable CDMO Product Portfolio
  102. 12.17.5 Gensenta Pharmaceuticals Recent Developments
  103. 12.18 BioTechnique
  104. 12.18.1 BioTechnique Company Information
  105. 12.18.2 BioTechnique Business Overview
  106. 12.18.3 BioTechnique Revenue in Sterile Injectable CDMO Business (2021-2026)
  107. 12.18.4 BioTechnique Sterile Injectable CDMO Product Portfolio
  108. 12.18.5 BioTechnique Recent Developments
  109. 12.19 Mithra CDMo
  110. 12.19.1 Mithra CDMo Company Information
  111. 12.19.2 Mithra CDMo Business Overview
  112. 12.19.3 Mithra CDMo Revenue in Sterile Injectable CDMO Business (2021-2026)
  113. 12.19.4 Mithra CDMo Sterile Injectable CDMO Product Portfolio
  114. 12.19.5 Mithra CDMo Recent Developments
  115. 12.20 S.C. Rompharm Company SRL
  116. 12.20.1 S.C. Rompharm Company SRL Company Information
  117. 12.20.2 S.C. Rompharm Company SRL Business Overview
  118. 12.20.3 S.C. Rompharm Company SRL Revenue in Sterile Injectable CDMO Business (2021-2026)
  119. 12.20.4 S.C. Rompharm Company SRL Sterile Injectable CDMO Product Portfolio
  120. 12.20.5 S.C. Rompharm Company SRL Recent Developments
  121. 12.21 Flagship Biotech International Pvt. Ltd
  122. 12.21.1 Flagship Biotech International Pvt. Ltd Company Information
  123. 12.21.2 Flagship Biotech International Pvt. Ltd Business Overview
  124. 12.21.3 Flagship Biotech International Pvt. Ltd Revenue in Sterile Injectable CDMO Business (2021-2026)
  125. 12.21.4 Flagship Biotech International Pvt. Ltd Sterile Injectable CDMO Product Portfolio
  126. 12.21.5 Flagship Biotech International Pvt. Ltd Recent Developments
  127. 12.22 Curida AS
  128. 12.22.1 Curida AS Company Information
  129. 12.22.2 Curida AS Business Overview
  130. 12.22.3 Curida AS Revenue in Sterile Injectable CDMO Business (2021-2026)
  131. 12.22.4 Curida AS Sterile Injectable CDMO Product Portfolio
  132. 12.22.5 Curida AS Recent Developments
  133. 12.23 BirgiMefar Group
  134. 12.23.1 BirgiMefar Group Company Information
  135. 12.23.2 BirgiMefar Group Business Overview
  136. 12.23.3 BirgiMefar Group Revenue in Sterile Injectable CDMO Business (2021-2026)
  137. 12.23.4 BirgiMefar Group Sterile Injectable CDMO Product Portfolio
  138. 12.23.5 BirgiMefar Group Recent Developments
  139. 12.24 Brooks Laboratories Limited
  140. 12.24.1 Brooks Laboratories Limited Company Information
  141. 12.24.2 Brooks Laboratories Limited Business Overview
  142. 12.24.3 Brooks Laboratories Limited Revenue in Sterile Injectable CDMO Business (2021-2026)
  143. 12.24.4 Brooks Laboratories Limited Sterile Injectable CDMO Product Portfolio
  144. 12.24.5 Brooks Laboratories Limited Recent Developments
13 Report Conclusion
    14 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst